Allogeneic stem cell transplantation for chronic myeloid leukemia

被引:41
作者
Barrett, J [1 ]
机构
[1] NHLBI, Stem Cell Allotransplantat Sect, Hematol Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1053/shem.2003.50003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:59 / 71
页数:13
相关论文
共 98 条
[11]   Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant:: in vivo and in vitro evidence for a graft-versus-leukaemia effect [J].
Childs, R ;
Epperson, D ;
Bahceci, E ;
Clave, E ;
Barrett, J .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (02) :396-400
[12]   Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [J].
Clark, RE ;
Dodi, IA ;
Hill, SC ;
Lill, JR ;
Aubert, G ;
Macintyre, AR ;
Rojas, J ;
Bourdon, A ;
Bonner, PLR ;
Wang, LH ;
Christmas, SE ;
Travers, PJ ;
Creaser, CS ;
Rees, RC ;
Madrigal, JA .
BLOOD, 2001, 98 (10) :2887-2893
[13]   Donor-recipient polymorphism of the proteinase 3 gene: A potential target for T-cell alloresponses to myeloid leukemia [J].
Clave, E ;
Molldrem, J ;
Hensel, N ;
Raptis, A ;
Barrett, AJ .
JOURNAL OF IMMUNOTHERAPY, 1999, 22 (01) :1-6
[14]   MARROW TRANSPLANTATION FOR CHRONIC MYELOID-LEUKEMIA - A RANDOMIZED STUDY COMPARING CYCLOPHOSPHAMIDE AND TOTAL-BODY IRRADIATION WITH BUSULFAN AND CYCLOPHOSPHAMIDE [J].
CLIFT, RA ;
BUCKNER, CD ;
THOMAS, ED ;
BENSINGER, WI ;
BOWDEN, R ;
BRYANT, E ;
DEEG, HJ ;
DONEY, KC ;
FISHER, LD ;
HANSEN, JA ;
MARTIN, P ;
MCDONALD, GB ;
SANDERS, JE ;
SCHOCH, G ;
SINGER, J ;
STORB, R ;
SULLIVAN, KM ;
WITHERSPOON, RP ;
APPELBAUM, FR .
BLOOD, 1994, 84 (06) :2036-2043
[15]   Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission [J].
Craddock, C ;
Szydio, RM ;
Klein, JP ;
Dazzi, F ;
Olavarria, E ;
van Rhee, F ;
Pocock, C ;
Cwynarski, K ;
Apperley, JF ;
Goldman, JM .
BLOOD, 2000, 96 (01) :86-90
[16]   Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis [J].
Craddock, C ;
Szydlo, RM ;
Dazzi, F ;
Olavarria, E ;
Cwynarski, K ;
Yong, A ;
Brookes, P ;
de la Fuente, J ;
Kanfer, E ;
Apperley, JF ;
Goldman, JM .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 112 (01) :228-236
[17]   Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors [J].
Davies, SM ;
DeFor, TE ;
McGlave, PB ;
Miller, JS ;
Verfaillie, CM ;
Wagner, JE ;
Weisdorf, DJ .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (05) :339-346
[18]   European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching [J].
Devergie, A ;
Apperley, JF ;
Labopin, M ;
Madrigal, A ;
Jacobsen, N ;
Carreras, E ;
Prentice, HG ;
Jouet, JP ;
Kolb, HJ ;
Herstenstein, B ;
Bacigalupo, A ;
Evensen, SA ;
Ljungman, P ;
deWitte, T ;
Reiffers, J ;
Nagler, A ;
Clark, RE ;
Goldman, JM ;
Gratwohl, A .
BONE MARROW TRANSPLANTATION, 1997, 20 (01) :11-19
[19]  
Dini G, 1998, BRIT J HAEMATOL, V102, P544
[20]   T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation [J].
Drobyski, WR ;
Hessner, MJ ;
Klein, JP ;
Kabler-Babbitt, C ;
Vesole, DH ;
Keever-Taylor, CA .
BLOOD, 1999, 94 (02) :434-441